ClinicalTrials.gg
RecruitingNCT06043908Updated Sep 21, 2023

The Effect of 0.05% CsA Eye Drops on Post-refractive Surgery Dry Eye

A Phase 4 interventional study of artificial tear eyedrops and 0.05% cyclosporine eyedrops in Dry Eye, sponsored by Peking University Third Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2023-09-21.

Sponsored by Peking University Third Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 10 months ago, but the record still lists the study as recruiting.
  • Registered 1 year after the study started (first participant enrolled Aug 2022, registered Sep 2023).
  • Started Aug 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Dry Eye Syndromes by Peking University Third Hospital — 2 open to participants now, 2 under way, none of them phase 3. Dry Eye Syndromes · Peking University Third Hospital.

Started
2022
with 2 others
Phase 4
4 of 14
1 open now
Registered
13th of 14
by date

Among the 14 studies in Dry Eye Syndromes by Peking University Third Hospital, this one is one of 3 that started in 2022, is one of 4 in phase 4, and was the 13th registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

2 of the 14 studies in Dry Eye Syndromes by Peking University Third Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Dry Eye Syndromes by Peking University Third Hospital, or all of them as a file.
02

Study summary

The purpose of this study is to observe the effect of 0.05% cyclosporine eyedrops combined with artificial tears in patients with dry eyes after corneal refractive surgery and to observe the changes in ocular surface characteristics and tear inflammatory cytokines before and after treatment.

Read the detailed description

The purpose of this study is to observe the effect of 0.05% cyclosporine eyedrops combined with artificial tears in patients with dry eyes after corneal refractive surgery and to observe the changes in ocular surface characteristics and tear inflammatory cytokines before and after treatment. At the same time, this study further observed whether 0.05% cyclosporine eyedrops combined with artificial tear eyedrops were more beneficial to ocular surface repair and tear film homeostasis compared with traditional artificial tears alone.

03

Conditions studied

  • Dry Eye

Browse trials for

Keywords

  • dry eye, refractive surgery, 0.05% cyclosporine
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who suffering from dry eye after refractive surgery with age between 18 and 45 years old.
  • Any gender.
  • Provision of written .

Exclusion criteria

Exclusion Criteria:

  • active ocular infection, ocular inflammation, active ocular allergy, severe blepharitis or obvious inflammation of the eyelid margin.
  • Pregnant and lactating women, or those planning a pregnancy over the course of the study.
  • Uncontrolled systemic disease.
  • Suffer from diseases that may affect corneal nerves, such as keratoconus, trigeminal neuralgia, allergic conjunctivitis, etc.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    0.05% cyclosporine eyedrops combined with artificial tear eyedrops

    0.05% cyclosporine eyedrops combined with artificial tear eyedrops

    Drug: artificial tear eyedrops · Drug: 0.05% cyclosporine eyedrops

  • Active comparator
    artificial tear eyedrops

    artificial tear eyedrops

    Drug: artificial tear eyedrops

Interventions

  • Drugartificial tear eyedrops

    The intervention group and control group were treated with artificial tear eyedrops four times a day.

  • Drug0.05% cyclosporine eyedrops

    The intervention group was treated twice a day.

06

What researchers measure

Primary outcomes

  1. ocular surface disease index (OSDI)

    OSDI is one of the most frequently used questionnaires for evaluation of dry eye disease (DED). This includes 12 questions which measure the frequency of symptoms over the recent week, and the scores range from 0 to 100.

    Time frame: from baseline to 3 months after treatment

  2. Tear break-up time (TBUT)(s)

    BUT is the time from normal blinking to the first appearance of a break in the tear film.

    Time frame: from baseline to 3 months after treatment

  3. Corneal fluorescein staining (CFS)

    The degree of fluorescein staining of the cornea was evaluated using the National Eye Institute (NEI) scale of five corneal regions (central, superior, temporal, nasal, and inferior). The scores range from 0 to 15.

    Time frame: from baseline to 3 months after treatment

  4. Schirmer I test (SIt) (mm/5 minutes)

    The Schirmer I test is performed using sterile strips without anesthesia. The strips are placed in the lateral part of the inferior fornix of the eye for 5min and the extent of tear flow down was measured in millimeters.

    Time frame: from baseline to 3 months after treatment

  5. Lissamine green staining

    To grade the temporal zone, the subject looks nasally; to grade the nasal zone the subject looks temporally. The upper and lower conjunctiva can also be graded.

    Time frame: from baseline to 3 months after treatment

Secondary outcomes

  1. the concentration of Interleukin-1β (IL-1β) (pg/ml)

    basal tears will be collected from the inferior meniscus of each subject to test this inflammatory cytokine. IL-1β levels will be quantified by Luminex immunoassay.

    Time frame: from baseline to 3 months after treatment

  2. the concentration of Interleukin-6 (IL-6) (pg/ml)

    basal tears will be collected from the inferior meniscus of each subject to test this inflammatory cytokine. IL-6 levels will be quantified by Luminex immunoassay.

    Time frame: from baseline to 3 months after treatment

  3. the concentration of Interleukin-10 (IL-10) (pg/ml)

    basal tears will be collected from the inferior meniscus of each subject to test this inflammatory cytokine. IL-10 levels will be quantified by Luminex immunoassay.

    Time frame: from baseline to 3 months after treatment

  4. the concentration of Interleukin-23 (IL-23) (pg/ml)

    basal tears will be collected from the inferior meniscus of each subject to test this inflammatory cytokine. IL-23 levels will be quantified by Luminex immunoassay.

    Time frame: from baseline to 3 months after treatment

  5. the concentration of Interleukin-17A (IL-17A) (pg/ml)

    basal tears will be collected from the inferior meniscus of each subject to test this inflammatory cytokine. IL-17A levels will be quantified by Luminex immunoassay.

    Time frame: from baseline to 3 months after treatment

  6. the concentration of tumor necrosis factor-α (TNF-α)(pg/ml)

    basal tears will be collected from the inferior meniscus of each subject to test this inflammatory cytokine. TNF-α levels will be quantified by Luminex immunoassay.

    Time frame: from baseline to 3 months after treatment

  7. the concentration of interferon-γ (IFN-γ)(pg/ml)

    basal tears will be collected from the inferior meniscus of each subject to test this inflammatory cytokine. IFN-γ levels will be quantified by Luminex immunoassay

    Time frame: from baseline to 3 months after treatment

  8. the concentration of granulocyte-macrophage colony-stimulating factor (GM-CSF)(pg/ml)

    basal tears will be collected from the inferior meniscus of each subject to test this inflammatory cytokine. GM-CSF levels will be quantified by Luminex immunoassay.

    Time frame: from baseline to 3 months after treatment

  9. the concentration of substance P (SP)(pg/ml)

    basal tears will be collected from the inferior meniscus of each subject to test this neuropeptide. SP levels will be quantified by Luminex immunoassay.

    Time frame: from baseline to 3 months after treatment

  10. the concentration of alpha-melanocyte-stimulating hormone (α-MSH) (pg/ml)

    basal tears will be collected from the inferior meniscus of each subject to test this neuropeptide. α-MSH levels will be quantified by Luminex immunoassay.

    Time frame: from baseline to 3 months after treatment

  11. the concentration of β-endorphin (pg/ml)

    basal tears will be collected from the inferior meniscus of each subject to test this neuropeptide. β-endorphin levels will be quantified by Luminex immunoassay

    Time frame: from baseline to 3 months after treatment

  12. the concentration of neurotensin (pg/ml

    basal tears will be collected from the inferior meniscus of each subject to test this neuropeptide. β-endorphin levels will be quantified by Luminex immunoassay.

    Time frame: from baseline to 3 months after treatment

  13. the concentration of oxytocin(pg/ml)

    basal tears will be collected from the inferior meniscus of each subject to test this neuropeptide. oxytocin levels will be quantified by Luminex immunoassay.

    Time frame: from baseline to 3 months after treatment

  14. corneal sensitivity (range, 60-0 mm)

    Corneal sensitivity will be measured in the right eye only using the Cochet-Bonnet aesthesiometer and the ascending method of limits to determine the threshold of stimulus detection.

    Time frame: from baseline to 3 months after treatment

  15. sub-basal corneal nerve density (mm/mm2)

    Sub-basal corneal nerve plexus image will be acquired using a laser scanning confocal microscope.

    Time frame: from baseline to 3 months after treatment

  16. numerical rating scale (NRS)

    The NRS was used to evaluate ocular pain and consists of a numbered line from 0 to 10 scores that measures pain intensity: 0-1: no pain; 2-4: mild pain; 5-7: moderate pain; and 8-10: severe pain.

    Time frame: from baseline to 3 months after treatment

  17. NPSI-Eye (range 0-100 score)

    Neuropathic Pain Symptom Inventory modified for the Eye (NPSI-Eye) (range 0-100 over a 24-hour recall period)

    Time frame: from baseline to 3 months after treatment

07

Study locations

1 of 1 sites recruiting
  • Hong Qi
    Beijing, Beijing 100191, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Dec 2023, 16 months after the start.

Of 85 non-industry phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's planned 16 months is above that.

Counting every sponsor, half of 113 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2023
First posted
Sep 21, 2023
StartActual
Aug 31, 2022
Primary completionEst.
Dec 31, 2023
CompletionEst.
Dec 31, 2023
Last update
Sep 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06043908
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Aug 31, 2022
Primary completion
Dec 31, 2023 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Sep 21, 2023

Study contacts

Hong Zhao
Contact
doctorqihong@163.com
13901066889 ext. 010
Lu Zhao
Contact
Drzl1996@163.com
+8619801152870 ext. 010
Hong Qi
principal investigator · Peking University Third Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion